The efficacy of fluorocarbon, surfactant, and their combination for improving acute lung injury induced by intratracheal acidified infant formula.
We conducted the current study to compare the efficacy of partial liquid ventilation (PLV), pulmonary surfactant (PSF), and their combination in ameliorating the acidified infant-formula-induced acute lung injury (ALI). In the Part I study, 42 rabbits receiving volume-controlled ventilation with positive end-expiratory pressure 10 cm H(2)O were randomly divided into 6 groups (groups noninjuryI, gas ventilation [GVi], PLVi, PSFi, PLVi-->PSFi, and PSFi-->PLVi). ALI was induced by intratracheal acidified infant formula (2 mL/kg, pH 1.8). Group GVi received neither PLV nor PSF therapy. Groups PLV and PSF received intratracheal fluorocarbon 15 mL/kg or surfactant 100 mg/kg, respectively, 30 min after acidified infant formula. Groups PLVi-->PSFi and PSFi-->PLVi received both treatments at 30-min intervals. In Part II, 42 rabbits (in 6 groups) undergoing pressure-controlled ventilation received the same drug therapies as in Part I. The lungs were excised to assess biochemical and histological damage 150 min after induction of ALI. In Parts I and II, PSF, fluorocarbon, and their combination attenuated lung leukosequestration and edema and superoxide production of neutrophils, consequently improving oxygenation, lung mechanics, and pathological changes. Independent of ventilation mode, PSF followed by fluorocarbon provided the most beneficial effects and fluorocarbon followed by PSF produced the least efficacy.
Nishina
Kahoru
K
Department of Anesthesia & Perioperative Medicine, Faculty of Medical Sciences, Kobe University Graduate School of Medicine, Kobe, Japan.
Mikawa
Katsuya
K
Takao
Yumiko
Y
Obara
Hidefumi
H
D000143:Acids; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D003611:Dairy Products / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005466:Fluorocarbons / Q000627:therapeutic use*; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D007225:Infant Food / Q000009:adverse effects*; D007231:Infant, Newborn; D007962:Leukocytes / Q000502:physiology; D008163:Luminescent Measurements; D008171:Lung Diseases / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D011015:Pneumonia, Aspiration / Q000188:drug therapy*; D011654:Pulmonary Edema / Q000503:physiopathology; D011659:Pulmonary Gas Exchange / Q000502:physiology; D011817:Rabbits; D012129:Respiratory Function Tests; D013501:Surface-Active Agents / Q000627:therapeutic use*
D000143:Acids; D005466:Fluorocarbons; D013501:Surface-Active Agents